By PPN News Staff
The FDA approved a regimen of 500 mg/m2 of cetuximab (Erbitux, ImClone) given intravenously over 120 minutes every two weeks for patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer (mCRC) or squamous cell carcinoma of the head and neck (SCCHN).
This approval provides for a biweekly dosage regimen option in addition to the previously approved weekly dosage regimen for the approved indications when cetuximab is used as a single agent or in combination with